Key result
Viral vector manufacturing requires major technological advancements to enable routine gene therapy for non-rare diseases.
This review highlights the current state and necessary advancements in large-scale manufacturing of viral vectors (AV, MLV, LV, AAV) to meet the growing demands of gene therapy.
Answers are grounded in this paper and cite their sources.
Manufacturing limits may delay gene therapy for common diseases; leaves open the need for vector production research.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Merten Ow (2017) conducted a review in Genetic diseases requiring gene therapy. Viral vector manufacturing was evaluated. Significant technological advancements in viral vector manufacturing are urgently required to meet the large-scale production demands for routine gene therapy of non-rare diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: